Results -Sensitivity, specificity, positive and negative predictive values of the two questions and GDS-30 15 for major and minor depression combined were calculated for different cut-off scores and a 31 receiver operating characteristics (ROC) analysis was conducted. A threshold of one or more positive 32 responses to the two screening questions gave a sensitivity of 100% and specificity of 84% (positive 33 predictive value 54%, negative predictive value 100%). The area under the ROC curve was 0.95. The 34 optimal cut-off for the GDS-15 was 5/6, which gave a sensitivity of 84% and specificity of 89% 35 (positive predictive value 59%, negative predictive value 97%), and the area under the curve was 36
INTRODUCTION 43
Parkinson's disease (PD) affects over 120,000 people in the UK, with about 10,000 newly diagnosed 44 each year [1] . Although PD is defined by its motor symptoms, non-motor symptoms such as 45 depression are also common. Research indicates that approximately 19% of PD patients meet DSM-46 47 [2] . 48 49 Depression has a negative impact on the quality of life of the PD patient and their family [3] , has a 50 negative effect upon motor symptoms [4] , cognitive functioning [5] , and functional ability [6] and is 51 associated with increased mortality [7] and greater medical and psychiatric co-morbidity [8] . 52 53 Diagnosis of depression in PD is not straight-forward because several clinical features of depression 54 and PD overlap. Symptoms of depression such as tiredness, lack of energy, psychomotor retardation, 55 mental slowing, impaired concentration, reduced appetite and insomnia occur in both depression 56
and PD making it difficult for clinicians to identify when depression is present. As a result depression 57 in PD is poorly recognised in clinical practice and depressive symptoms are frequently missed during 58 specialist reviews [9] . 59 60 The U.K. National Institute for Health and Clinical Excellence (NICE) [10] recommend screening for 61 depression in patient groups at higher risk of depression, and suggest the use of two screening 62 questions [11] In light of this recommendation and growing evidence that antidepressant treatment in PD is 69 effective [12] , it is important that clinicians consider routine screening of PD patients. This study 70 aimed to investigate the effectiveness of these questions for screening for depression in a PD 71 outpatient setting. As a comparator we used the 15 item version of the Geriatric Depression Scale 72 Sensitivity (Se), specificity (Sp), positive and negative predictive value (PPV, NPV), positive and 100 negative likelihood ratio (LR+, LR-) and the diagnostic odds ratio (DOR) were calculated. Receiver 101 operating characteristic (ROC) curve analyses were carried out using the methods described by 102 Altman [20] and the areas under the curves (AUC) were compared using the methods described by 103 Hanley and McNeil [21] . Analyses were performed using SPSS v18. 104 105 106
RESULTS

107
A total of 136 patients participated in the study between 2007 and 2011 -15 were excluded due to 108 scoring less than 24 on the MMSE and one patient declined to continue following the SCAN 109 interview. Data were therefore available for 120 participants ( 
117
A total of 17 participants responded positively to one of the two NICE screening questions, and 18 118 responded positively to both. A threshold score of 1 (i.e. a positive response to one or more of the 119 questions) gave optimal performance for the purpose of screening for depression in PD patients 120 (Table 2) . Table 3 shows the results for different cut-off scores for the GDS-15; the optimal screening 121 cut-off was 5/6. 122 123 Table 2 . Operating characteristics of the two NICE screening questions for the identification of DSM-124 IV minor or major depression, and for the identification major depression 125 This study was designed to assess the validity of the two depression screening questions 156 recommended by NICE [22] in PD patients attending a hospital out-patient PD clinic. The two-157 question measure appears to be a useful tool to identify participants with major or minor depression 158 in this setting. With a threshold of a 'Yes' response to either of the two questions, all cases of 159 depression were correctly identified in this study sample (100% sensitivity) and two 'No' responses 160 correctly identified 84% of all non-depressed (84% specificity). This detection rate should come as no 161 surprise, as the two screening questions reflect the core symptoms of major depression in DSM-IV 162 (that is, at least one of these symptoms is required to be present when making a diagnosis of 163 depression). 164
165
In our study the GDS-15 also demonstrated good test characteristics -at a threshold score of 5/6 for 166 major and minor depression it showed 84% sensitivity, 89% specificity and PPV of 59%. The GDS-15 167 is already established as a valid tool for screening for depression in PD [23] , and although relatively 168 brief still takes longer to complete and to score than the two-question measure. The brevity of the 169 two questions recommended by NICE lends itself to easy integration into routine clinical assessment 170 and review. The high sensitivity of these questions means that most cases of depression will be 171 identified, but a PPV of 54%, shows that nearly half the people who tested positive on the two 172 questions were false-positives. In a screening programme in a clinical setting this could lead to 173 unnecessary further investigation in many non-depressed patients. Depending on the action taken 174 following a positive depression screening result (e.g. a diagnostic interview performed by the clinic 175 doctor or referral for specialist assessment) this may not be acceptable. At the very least, if a patient 176 responds positively to either of the NICE screening questions it should prompt the clinician to 177 question them further regarding their mood. In our study half of the non-depressed participants 178 identified as depressed by the NICE screening questions had sub-threshold depression or other 179 mental health issues (e.g., significant anxiety symptoms or unresolved bereavement). These 180 participants would benefit from further investigation or support despite not meeting diagnosticcriteria for depression, and would clearly be worth identifying in a clinical context especially as co-182 morbid anxiety and depression are common in PD [24] . 183 184 NICE guidelines for depression [22] sensitivity and specificity for all of the scales. The authors felt that the GDS-30 was the most efficient 227 scale for screening in clinic because it was a self-report measure and had favourable psychometric 228 properties (sensitivity 72%, specificity 82%, PPV 73% and NPV 81%). The GDS-15 and the two NICE 229 screening questions have shown slightly better performance in this study, except in terms of PPV, 230 and have the advantage of being shorter scales than the GDS-30. One recent study has investigated 231 the utility of an ultra-short scale -the PHQ-2 [28]. This scale uses the same two items from the 232 PRIME-MD [29] as the NICE questions. In the PHQ-2 the reference time period is two weeks rather 233 than the last month, and items are rated on a scale from 0 (not at all) to 3 (nearly every day). The 234 study found the two-item scale to be a valid screening measure in PD (sensitivity 75%, specificity89%, PPV 70% and NPV 91% at a cut-off score of 3 out of 6) but although the scale is short the 236 scoring is less simple than the yes/no response used for the NICE screening questions. The data here 237
indicates that the two NICE questions may offer good psychometric properties as well as being 238 extremely quick to complete, with a threshold that is very easy to apply. 239 240 Evidence suggests that screening for depression improves recognition of depression but does not 241 necessarily lead to improvement in depression symptoms for the patient [30] . Screening needs to 242 take place in the context of a system which enables accurate diagnosis following positive screening, 243 effective treatment and appropriate follow-up in order to achieve positive clinical benefits [31] . This 244 study shows that the two questions recommended for screening for depression in the NICE 245 guidelines are a useful means of identifying depression in patients with PD, who do not have 246 significant cognitive impairment. They could be easily assimilated into routine practice and their 247 brevity suggests they would be more acceptable to clinician and patients compared to longer 248 instruments. If widespread use of the screening questions is adopted, the clinical challenge will be 249 ensuring the accurate diagnosis of patients that screen positive; whether it is by the PD specialist 
3-5 KEY POINTS 256
• The two questions recommended by NICE for screening for depression perform well in 257 identifying depression in patients with PD who do not have significant cognitive impairment. 258
• The two questions could easily be assimilated into routine assessment and review of patients 259 with PD. 260
• A two-stage screening process, with a scale such as the GDS-15, can reduce the number of 261 false-positives.
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